This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ICV Partners Establishes Dialysis Treatment Platform With Acquisition Of Atlantis Healthcare Group Puerto Rico, Inc.

NEW YORK, March 19, 2013 /PRNewswire/ -- ICV Partners (ICV), a leading investment firm focused on lower middle market companies, announced today that it has established a kidney dialysis treatment platform with the acquisition of Atlantis Healthcare Group Puerto Rico, Inc. ("Atlantis"), one of the island's leading providers of kidney dialysis services. 

Concurrent with the transaction, ICV, in partnership with Dr. Randall Maxey, Dr. Otegbola Ojo, and Ms. Ruby Harford, is forming American Alliance Dialysis Holdings, LLC ("AAD") to identify and evaluate strategic investment opportunities in North America and the Caribbean.  Dr. Maxey, a noted nephrologist who has nearly 40 years of nephrology experience and developed a series of successful dialysis centers in both the private and non-profit sectors, will become Chairman and CEO of AAD.  Ms. Harford, who brings over 30 years of administrative nursing and executive healthcare experience, will be Chief of Clinical Operations and Regulatory Affairs of AAD.

Atlantis, headquartered in Trujillo Alto, was founded in 2000 by Dr. Otegbola Ojo and has since grown into Puerto Rico's second largest provider of kidney dialysis services for patients suffering from end-stage renal disease ("ESRD").  With 13 facilities strategically located throughout the island of Puerto Rico, Atlantis provided approximately 200,000 treatments last year and currently has a patient census of nearly 1,400.  Atlantis also contracts with 12 hospital networks to provide inpatient acute dialysis services.

Dr. Ojo, a leading nephrologist who prior to founding Atlantis established several dialysis programs in Canada and the Caribbean, retains a significant ownership position.  He continues with the new organization as President and Chief of Operations and Strategy of AAD and maintains his role as President of Atlantis.

Cory Mims, Managing Director of ICV, said, "We are excited to have AAD as our first investment for ICV Partners III.  Dr. Ojo has built Atlantis into a strong player within its current market.  We look forward to leveraging Dr. Maxey's medical expertise and strong relationships with nephrologists throughout the U.S. to develop a significant position for AAD in the U.S. dialysis market over the next several years.  AAD is now well-positioned as a platform investment and we expect to grow the business by pursuing a number of strategic and organic expansion opportunities while, at the same time, identifying new ways to continue providing the highest quality patient care."

Dr. Maxey said, "Atlantis has a successful track record of growth in Puerto Rico and integrating new facilities into its network.  We will continue to grow in Puerto Rico by adding new dialysis treatment facilities.  In addition, because of the fragmented nature of the industry in the U.S., we will be able to tap into a rich pipeline of opportunities as we execute strategic acquisitions and grow AAD into new geographic areas."

Dr. Ojo, said, "Atlantis is an outstanding company and our highly skilled management team, outstanding physicians, and compassionate medical staff provide the highest standards of patient care with a unique integrated focus on quality of life to over one thousand patients each year.  There continues to be a growing need for dialysis treatment and I believe our new partnership with ICV will prove to be extremely valuable as we seek ways to ensure better patient outcomes." 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs